FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 426 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results October 4, 2024 New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... December 7, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib July 28, 2020 One in Five of Older Patients with EBC Treated in a... December 13, 2022 Load more HOT NEWS Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t... New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Lung cancer screening can’t leave anyone in the UK behind
